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ABSTRACT - PURPOSE: Breast cancer resistance protein (BCRP/ABCG2) is a drug efflux transporter 
expressed at the blood cerebrospinal fluid barrier (BCSFB), and influences distribution of drugs into the 
central nervous systems (CNS). Current inhibitors have failed clinically due to neurotoxicity. Novel 
approaches are needed to identify new modulators to enhance CNS delivery. This study examines 18 
compounds (mainly phytoestrogens) as modulators of the expression/function of BCRP in an in vitro rat 
choroid plexus BCSFB model.   METHODS:  Modulators were initially subject to cytotoxicity (MTT) 
assessment to determine optimal non-toxic concentrations. Reverse-transcriptase PCR and confocal 
microscopy were used to identify the presence of BCRP in Z310 cells. Thereafter modulation of the 
intracellular accumulation of the fluorescent BCRP probe substrate Hoechst 33342 (H33342), changes in 
protein expression of BCRP (western blotting) and the functional activity of BCRP (membrane insert model) 
were assessed under modulator exposure. RESULTS: A 24 hour cytotoxicity assay (0.001 µM-1000 µM) 
demonstrated the majority of modulators possessed a cellular viability IC50 > 148 µM. Intracellular 
accumulation of H33342 was significantly increased in the presence of the known BCRP inhibitor Ko143 
and, following a 24 hour pre-incubation, all modulators demonstrated statistically significant increases in 
H33342 accumulation (P < 0.001), when compared to control and Ko143. After a 24 hour pre-incubation 
with modulators alone, a 0.16-2.5 -fold change in BCRP expression was observed for test compounds. The 
functional consequences of this were confirmed in a permeable insert model of the BCSFB which 
demonstrated that 17-β-estradiol, naringin and silymarin (down-regulators) and baicalin (up-regulator) can 
modulate BCRP-mediated transport function at the BCSFB. CONCLUSION: We have successfully 
confirmed the gene and protein expression of BCRP in Z310 cells and demonstrated the potential for 
phytoestrogen modulators to influence the functionality of BCRP at the BCSFB and thereby potentially 
allowing manipulation of CNS drug disposition.   
 
This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For 
Readers”) may comment by clicking on ABSTRACT on the issue’s contents page. 
_______________________________________________________________________________________ 
 
INTRODUCTION 
 
The blood-brain barrier (BBB) and the blood-
cerebrospinal fluid barrier (BCSFB) are the two 
primary barriers across which endogenous 
nutrients and hormones and exogenous chemicals 
must transverse in order to gain access to the 
central nervous system (CNS).  The BBB and 
BCSFB are often termed the gatekeepers to the 
CNS and play an obvious role in controlling the 
neuronal microenvironment. In recent years the 
importance of the BCSFB as a site for drug 
metabolism and in governing the composition of 
cerebrospinal fluid (CSF) has gained more 
attention due to its significance in normal 
physiology and disease pathology (1). The 
BCSFB is formed from the epithelial cells of the 
choroid plexus (CP) facing the CSF, which are 
sealed by the tight junctions (2). 
 
 
The choroid plexuses are located within the 
brain ventricles: one in each lateral ventricle, the 
third ventricle and fourth ventricle.  The CP 
epithelium is a dynamic tissue which has a greater 
perfusion rate compared to the cerebral blood 
flow and weighing only 2 g (3-6). It secretes CSF 
at a rate of  25 mL/hour in humans (7) which 
helps to maintain brain extracellular fluid (ECF) 
and CSF homeostasis (2, 8) as well as providing 
mechanical support to the brain, removal of 
metabolic products (9) and as a route for the 
distribution of nutrients, neurotransmitters and 
hormones across the CNS (10, 11) (12, 13). 
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A key component of the protective 
mechanism of the BCSFB is the expression of a 
variety of ATP-Binding Cassette (ABC) 
transporter proteins (14-18), which play a 
significant role in drug transport across the 
BCSFB. A key member of the ABC family of 
transporters is the breast cancer resistance protein 
(BCRP/ABCP/MXR).  BCRP is the second 
member of the G-subfamily of transporter 
proteins, and derives it names from the result of 
its almost simultaneous identification in the drug-
resistant breast cancer cell line MCF-7/AdrVp 
(19), human placenta (ABCP) (20) and in a 
mitoxantrone-resistant cell line (MXR) (21).  
BCRP mRNA encodes for a 655-amino acid, 
72 kDa protein which forms a single nucleotide 
binding domain (NBD) and six transmembrane 
domains (TMD), hence is often termed a half-
transporter.  The endogenous function of BCRP is 
varied, and can be found expressed in stem cells 
(22-24), the apical membrane of enterocytes, the 
liver canaliculi, the proximal tubules of the 
kidneys, the BBB and BCSFB, the blood-testes 
barrier and the blood-placental barrier and blood-
retinal barriers (25-29). The localisation at key 
secretory organs results in BCRP imparting a 
‘protective’ pharmacokinetic function for human 
physiology and limits access of drugs to various 
tissues. 
Much work has focused on the role of BCRP 
in governing drug penetration across the BBB and 
rodent knock-out systems have implicated BCRP 
playing a more complicated role in cooperation 
with other transporter proteins to limit BBB 
penetration of drugs, e.g. topotecan (30). 
Furthermore position-emission tomography 
studies with tariquidir (31), gefitinib (32, 33), 
sorafenib (34), CEP-32496 (35) have confirmed 
the importance of BCRP at the BBB. At the 
BCSFB, only a handful of reports have 
demonstrated expression in the choroid plexus of 
mice (36), rats (37) and humans (38). The 
localisation of BCRP at the CSF side suggests 
that it would facilitate but not restrict the transport 
to the CSF (37, 38). 
In vitro and in vivo inhibition of BCRP is of 
great interest for improving the pharmacokinetics 
of therapeutics. The first series of reported 
inhibitors included cyclosporine A, pantoprazole 
and verapamil but demonstrated limited clinical 
efficacy due to significant toxicity and 
interactions with CYP3A (39, 40). Second 
generation inhibitors included topotecan, 
irinotecan, gefitinib and SN-38 but again 
demonstrated limited clinical application due to a 
range of cytotoxicity concerns and high potential 
for drug-drug interactions (39, 41). Third 
generation inhibitors represent molecules that 
have been recently developed and include the 
fungal toxin derived fumitremorgin C (FTC) (42, 
43), GF120918, Ko143 (43-45) but again 
widespread clinical use is limited due to an 
uncertain safety profile (43). Therefore, there is 
an urgent need to identify novel inhibitors of 
BCRP with a tolerable safety profile. 
To this end, a novel class of compounds that 
have gained interest as potential candidates are 
phytoestogens, of which flavonoids are the most 
chemical group.  Flavonoids are polyphenolic 
compounds found in fruit, vegetables and many 
herbal products.  In the U.S. the average daily 
intake of flavonoids has been estimated to be at 1 
g (46).  In epidemiological and animal studies, 
flavonoids have been suggested to be possess 
anti-inflammatory (47, 48), anti-oxidative, 
antithrombogenic (49, 50), anti-tumour (51) and 
anti-viral (52, 53) effects.  
Numerous studies have demonstrated a direct 
interaction of flavonoids with BCRP, resulting in 
the modulation of its activity (Table 1). 
 
 
Table 1. Various cell lines studied to investigate at the interaction of flavonoids with BCRP. 
Cell line   Flavonoid Reference 
MCF-7 Apigenin, genistein, naringenin, quercetin, biochanin A, hesperitin, 
silymarin and fistein 
(54-58) 
NCI-H60  Apigenin, naringenin, quercetin, biochanin A, hesperitin, silymarin 
and fistein 
(56, 57) 
BT-474 Apigenin and genistein (54, 58) 
T47-D Apigenin and genistein (54) 
Caco-2 Apigenin, genistein, naringenin, quercetin, biochanin A, hesperitin, 
silymarin and fistein 
(59-62) 
K562 		 Rutin, hespiridin and silymarin (55) 
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The impact of flavonoids/modulators on CNS 
drug disposition is highlighted in Figure 1. Under 
‘normal’ physiological conditions BCRP would 
play a role in the efflux of substrates from the 
brain endothelial microvascularate back into the 
systemic circulation and thereby limiting brain 
ISF exposure. At the BCSFB BCRP would 
potentially enhance the disposition of drugs into 
the CSF, with potential CSF-ISF mixing before 
exiting through CSF drainage routes. This overall 
balance of drug disposition would therefore 
favour the CSF. Where flavonoids/modulators are 
thought to either directly inhibit or down-regulate 
BCRP protein expression, the effects would be 
reversed with enhanced BBB penetration and 
brain ISF disposition coupled with diminished 
delivery across the BCSFB and into the CSF (due 
to the lack of CSF penetration enhancement 
provided by BCRP under normal conditions). 
Under circumstances where BCRP is induced, the 
balance of disposition would favour CSF delivery 
provided by the enhanced additional transport in 
the blood-CSF as a result of increased abundance 
of BCRP at the BCSFB. 
In the current study, we identified and 
investigated the genomic and protein expression 
of BCRP in immortalised rat choroid plexus cells 
and the potential for modulation of BCRP-
mediated transport at the BCSFB using reported 
phytoestrogenic and non-phytoestrogenic 
modulators of BCRP expression and function to 
ascertain whether such modulators can be 
employed as agents to alter the disposition of 
transporter substrates at the BCSFB. 
 
MATERIALS AND METHODS 
 
Materials 
Dulbecco’s modified essential media with glucose 
(DMEM), fetal bovine serum (FBS), amphotericin 
B, penicillin/streptomycin  and gentamycin were 
obtained from Biosera (Sussex, UK); Resveratrol 
and Ko143 from Santa Cruz Biotechnology 
(Texas, USA); Curcumin from Cayman Chemical 
(Cambridge, UK); Rat tail I collagen solution 
from First Link (Birmingham, UK) and all other 
chemicals were sourced from Sigma (Dorset, 
UK). GenElute Total RNA extraction kits were 
purchased from Sigma (Dorset, UK); My TaqTM 
one-step RT-PCR kit and Easy Ladder I obtained 
from Bioline (London, UK). All PCR primers 
were designed synthesised by IDTDna (Leuven, 
Belgium); Optiblot SDS-page gel and western 
blot reagents obtained from Abcam (Cambridge, 
UK); ABCG2 (M-70), beta-actin (C4), broad 
range markers, goat anti-rabbit IgG-FITC and 
protease inhibitor cocktail were obtained from 
Santa Cruz Biotechnology (Texas, USA). Stock 
solutions of all test compounds were prepared in 
dimethylsulfoxide (DMSO) and stored at -20°C 
until use. 
 
Cell culture  
The rat choroid plexus cell line Z310 was a kind 
gift from Dr. Wei Zheng (Purdue University, 
West Lafayette, USA). The cells were maintained 
in the medium as described by Zheng et al (63) 
with minor modifications. In brief, cells were 
grown in DMEM supplemented with 4.5 g/L 
glucose, 10% FBS, 100 IU/mL penicillin, 100 
µg/mL streptomycin, 2.5 mg/mL gentamycin, 
amphotericin B and epidermal growth factor 
(EGF) to a final concentration of 10 ng/mL in a 
humidified atmosphere of 5% CO2 at 37°C. Cells 
were used at passages 224-260. 
 
Reverse–transcriptase polymerase chain 
analysis 
RNA was extracted according to manufacturer’s 
instructions. In brief, cells were seeded at cell 
density of 5x104 per well in a 6-well plate. Cells 
were lysed and transferred into a GenElute Total 
RNA mini prep kit filtration column and 
centrifuged at 12,000 x g for 2 minutes. The 
lysate was transferred into a fresh column and 
centrifuged. The column was washed twice with 
wash solution and 50 µL of the elution solution 
was added into the binding column and 
centrifuged. The concentration of total extracted 
RNA was quantified by a Nanodrop system 
(Thermo Scientific, Nanodrop 1000). 
RNA amplification was conducted using the 
My Taq One-Step RT-PCR kit according to the 
manufactures instructions. The PCR primers used 
were as follows: TTR (accession number: 
NM_022712) forward primer 5’- 
ATTAGAGCTTGGTGCATGCCT, reverse 
primer 5’- GGCCACAACTCACTGGACTT; β-
actin (accession number: NM_031144) forward 
primer 5’- CCCGCGAGTACAACCTTCTT and 
reverse primer 5’-
AACACAGCCTGGATGGCTAC; BCRP 
(accession number: NM_181381) forward primer 
5’ - TGTGAGCCCTACAACAACCC, reverse 
primer 5’ - AAAAAGCCTCCACCGTCCTC.  
The thermal cycle was run as recommend by the 
manufacturer’s kit and the amplified products 
were separated and visualised using a 1% agarose 
gel stained with ethidium bromide.  
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Figure 1. Balance of drug disposition at the BBB and BCSFB during normal physiological function of BCRP (top), 
when BCRP is inhibited or down-regulated (middle) and when BCRP is up-regulated (bottom). Arrows indicate the 
direction of flux; blue triangles indicate the overall balance of disposition; B: BCRP; CSF: cerebrospinal fluid; ISF: 
interstitial fluid. 
 
 
Immunofluorescence  
Approximately 15,000 cells were seeded onto 
glass cover slips for 48 hours and subsequently 
washed with phosphate buffered saline (PBS) 
three times and fixed with 4% paraformaldehyde 
for 10 minutes at room temperature (RT), washed 
a further three times with PBS and blocked with 5 
% goat serum in Tris buffer saline tween-20 
(TBST) for 30 minutes at RT. The blocking buffer 
was removed and incubated with primary 
antibody (ABCG2 M-70) for 2 hours at RT. Cells 
were washed again with the PBS and incubated 
with goat anti-rabbit IgG-FITC in the dark for 1.5 
hours at RT and mounted with DAPI-containing 
mounting media.  
 
Confocal Laser Scanning Microscopy 
The cover slips were analysed using an upright 
confocal microscope (Leica SP5 TCS II MP) and 
visualised with a 40x oil immersion objective. All 
images were acquired using an argon laser at 494 
nm to visualise FITC and a helium–neon laser to 
visualise DAPI at 461 nm.  
 
Modulators 
A total of 18 modulators (Table 2) consisting 
primarily of flavonoids, were dissolved in DMSO 
and stored at -20°C until required. 
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Table 2. Modulators of BCRP used in this study 
Modulator Class Name Impact on BCRP 
Diarylheptanoid Curcumin 
SD Rats (Inhibition) (64);  FVB Mice (Inhibition: Increase in 
Cmax and AUC0-8) (65); Humans (Inhibition: Increase in Cmax and 
AUC0-24) (64); MCF-7 (Induction) (66) 
Flavone Apigenin MCF-7 MX100 and NCI-H460 MX20 (Inhibition) and K562/BCRP (Inhibition) (67)                       
Flavone Baicalin Caco-2 (Substrate) (68) 
Flavone Chrysin Caco-2 (Inducer-mRNA) (66) 
Flavone Flavone Caco-2 (Inducer-mRNA) (66) 
Flavone α-napthoflavone Aryl-Hydrocarbon Receptor [AhR] antagonist (BCRP regulator) (69) 
Flavone 6,2,4-Trimethoxy-flavone (TMF) 
Aryl-Hydrocarbon Receptor [AhR] antagonist (BCRP regulator) 
(70) 
Flavonol Fisetin MCF-7 MX100 and NCI-H460 MX20  (67) 
Flavonol Quercetin Caco-2 (Inducer-mRNA) (66); HEK293/BCRP (71);   MCF7/MX, K562/BCRP (Inhibition) (72) 
Flavonol Reservatrol 
Aryl-Hydrocarbon Receptor [AhR] antagonist (BCRP regulator) 
(73);  
Caco-2 and MCF-7 (Inducer-Protein) (66). 
Flavonol glycoside Rutin Membrane vesicles (Inhibition) (74) 
Flavonolignan Silymarin 
MCF-7 MX100 and NCI-H460 MX20 (Inhibition) 
(67);  
Caco-2 (Inducer-Protein) (66) 
Flavanone  Hesperidin Unknown 
Flavanone  Hesperetin MCF-7 MX100 and NCI-H460 MX20 (Inhibition) (67) 
Flavanone 
glycoside Naringin MCF-7 MX100 and NCI-H460 MX20 (Inhibition) (67) 
O-methylated 
isoflavone Biochanin A MCF-7/MX100 (Inhibition) (67, 75) 
Polycyclic aromatic 
hydrocarbon Benzo(a)pyrine (BAP) 
Aryl-Hydrocarbon Receptor [AhR] agonist (BCRP regulator)  
leading to BCRP modualtion (76) 
Oesteogens 17-β-Estradiol 
Estrogen receptor agonist (BCRP regulator) and  
SD Rats (Inhibition) leading to pronounced BCRP downregulation 
(77)     
  
 
Cytotoxicity assay 
5x104 cells per well were seeded into the 96-well 
plate and allowed to attach for 24 hours. The 
media was subsequently removed and cells 
washed with PBS, followed by the addition of 200 
µL of growth media containing modulators per 
well across a seven-fold log concentration range 
(0.001-1000 µM) and incubated for 24 hours at 
37°C in a 5% CO2 air humidified environment. 
Thereafter 20 µL of 5 mg/mL 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) dissolved in PBS was added to 
each well and incubated at 37°C, 5% CO2 in an air 
humidified environment for 4 hours. After 
incubation the medium was removed and 100 µL 
of DMSO was added. Plates were left in dark for 
5-15 minutes and the UV-absorbance of the 
formazan product was determined at 595 nm. 
Each concentration was assayed in eight wells and 
run in three independent experiments and results 
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expressed as percentage cytotoxicity relative to a 
non-modulator control (exposed to 0.5% DMSO 
only). 
 
Hoechst 33342 intracellular accumulation 
assay  
To assess the impact of modulators on the 
intracellular accumulation of a BCRP substrate, a 
fluorescent BCRP substrate, Hoechst 33342 
(H33342), was utilised in a 96-well plate format 
accumulation assay. 2 x104 cells were seeded into 
each well of 96-well plate and allowed to attach 
for 48 hours. The media was removed and cells 
were washed twice with 100 µL warm Hanks 
balances salt solution (HBSS) and pre-incubated 
with an optimal concentration of modulator (as 
determined from the MTT assay) for 24 hours in 
cell culture media with a no-modulator control 
(0.5% DMSO). After 24 hours the cells were 
washed with ice cold HBSS and incubated with 
25 µM H33342 alone, for one hour in HBSS 
supplemented with 10mM HEPES.  For 
comparison to the known specific BCRP inhibitor 
Ko143, cells were pre-incubated for only 1 hour 
before incubating with H33342. 
At the end of the incubation period, media 
was removed and cells were washed with ice cold 
HBSS and 100 µL of the lysis buffer (50 mM 
Hepes, 200 mM NaCl, 5% glycerol and 0.5% 
triton-X) was added into each well and the plates 
shaken on an orbital plate shaker (500 rpm for 2 
minutes) before being incubated in the dark for 30 
minutes. The wells were read on fluorescent plate 
reader SpectraMax MX5 reader (Molecular 
Devices LLC, Sunnyvale, CA) with an excitation 
wavelength of 355 nm and emission of 460 nm. 
Each modulator was assayed in eight wells and 
run in three independent experiments.  
The impact of modulator fluorescence 
interfering and overlapping with the fluorescence 
of H33342 was assessed in a cell-free system 
using identical modulator and H33342 
concentrations used in the intracellular 
accumulation assay on a 96-well plate. 100 µL of 
each modulator and H33342 were added to wells 
(quadruplicate) of a 96-well plate and 
fluorescence measured with an excitation 
wavelength of 355 nm and emission of 460 nm.   
 
Modulation of BCRP protein expression 
To assess the impact of modulator exposure on 
BCRP protein expression, cells were grown in a 
25cm2 flasks for 2-3 days or until confluent and 
treated with 25 µM of modulator (unless 
otherwise stated) for 24 hours. Cells were washed 
with warm PBS and whole cell lysate were 
obtained by trypsinised with 0.5% trypsin-EDTA. 
The cell suspension was centrifuged at 1500 rpm 
for 10 minutes and supernatant was discarded. 
Freshly prepared ice cold RIPA buffer (1xTBS, 
1% Nonidet P-40, 0.5% sodium deoxycholate, 
0.1% SDS, 0.004% sodium azide, 0.01% PMSF 
solution, sodium orthovanadate and protease 
inhibitor cocktail) was added. The lysate was 
homogenized by ultra-sonication on ice. Cell 
debris was removed by centrifugation for 30 
minutes at 16,000 x g and 4°C.  
The supernatant was collected and protein 
content was determined by a bicinchoninic acid 
assay (BCA). Approximately, 75 µg of protein 
was loaded into each well and transferred onto a 
PVDF membrane. The membrane was incubated 
overnight at 4°C with a 1:500 dilution of BCRP 
primary antibody (ABCG2-M70). The blot was 
then incubated with a 1:7500 dilution of a HRP-
conjugated secondary antibody (goat anti-rabbit 
IgG conjugated with horseradish peroxidase) on a 
shaker for 2 hours at RT.  For detection of the 
loading control (β-actin) a 1:5000 dilution of a 
HRP-conjugated beta-actin antibody (C4) was 
used.  Bands were visualised by a laboratory 
made enhanced chemiluminescence (ECL) 
solution (90 mM p-coumaric acid, 250 mM 
luminol, 1M tris and 30% H2O2) before 
development. 
 
In vitro BCSFB model: modulation of BCRP 
transport function 
Directional transport experiments were conducted 
in Z310 cells to evaluate the functional activity of 
BCRP in Z310 cells and to assess the impact of 
pre-incubation of cells with BCRP modulators on 
the apical-to-basolaterial (CSF-to-blood) transport 
of the BCRP substrate sulfasalazine. The porous 
polyester membrane attached to the inner chamber 
of a 1.12 cm2 permeable insert (ThinCert®) was 
pre-coated with 0.01% collagen for 3-4 hours. 
The inserts were washed twice with PBS and 1 
mL of cell suspension containing 2.0x105 cells in 
cell culture media supplemented 1 µM 
dexamethasone (78) was added to the insert 
chamber and 1.5 mL of cell culture media added 
to the outer well. The cell monolayer was formed 
4-6 days post-seeding and was confirmed by the 
formation of apical ‘CSF’ for 24 hours, TEER 
value of 60 ± 5 Ω.cm2 (63, 78-83) and < 1 % 
lucifer yellow permeation. 
Transendothelial electrical resistance was 
measured using chop-stick electrodes and 
corrected for background resistance (collagen-
coated inserts without cells) and by the surface 
area of the insert (1.12 cm2). Lucifer yellow (LY) 
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permeability assays were conducted using 100 
µM of LY (prepared in HBSS) added apically and 
incubated for 60  minutes at 37 °C before 100 µL 
samples were removed from the basolateral well. 
The permeation of LY was assessed using a 
fluorescent plate reader (SpectraMax MX5 reader: 
Molecular Devices LLC, Sunnyvale, CA), with an 
excitation wavelength of 485 nm and emission of 
530 nm. 
For transport studies the media was replaced 
with fresh maintenance media supplemented with 
25 µM of the modulator and incubated for 24 
hours. Thereafter inserts were washed with warm 
serum free maintenance media (SFM) and 
incubated with SFM for 30 minutes to equilibrate. 
Following this equilibration period, 1 mL fresh 
SFM was spiked with 10µM sulfasalazine for all 
wells (with no modulators) and for control wells, 
1 µM Ko143, added to the insert well and 1.5 mL 
of warm SFM added to the outer well. Samples 
were taken from the outer well at 0, 30, 60, 90, 
120, 150, 180 and 210 minutes, replaced with 
fresh warn SFM and sulfaslazine concentrations 
analysed by HPLC analysis and corrected for 
volume replacement. 
 
The apical-to-basolateral apparent permeability 
coefficient was calculated according to equation 
1: 
0
AB,app AC
1
dt
dQP   (1) 
where Papp,AB (cm/s) is the apparent permeability 
coefficient, dQ/dt the amount of drug permeated 
per unit of time and is calculated from the 
regression line of time points of sampling, A 
(cm2) is the insert surface area (1.12 cm2) 
available for permeation and C0 the initial drug 
concentration in the donor compartment. 
 
High-performance liquid chromatography 
analysis  
The isocratic HPLC method utilised within this 
study was derived from the studies of Elmasry et 
al., (2011).  The HPLC analyses (Shimadzu, LC-
2010A HT) of the samples were performed on a 
reversed-phase C18 column (Phenomenex Luna 
5-µm) with a mobile phase consisting of 70:29:1 
methanol:millQ water:acetic acid, with a flow rate 
of 1 mL/min and a retention time of 7 minutes. In 
our studies a linear correlation was reported up to 
50 µM (r2=0.998) for sulfasalazine prepared in 
HBSS transport buffer and detected at 365 nm.  
The lowest limits of quantification were 0.025 
µM. 
 
STATISTICAL ANALYSIS 
 
Unless otherwise stated, three independent 
experiments were carried out for each test 
compound. Statistical significance was evaluated 
by one-way ANOVA or paired two-tail Students 
t-test using GraphPad Prism version 5.00 for 
Windows (GraphPad Software, La Jolla 
California USA, www.graphpad.com). 
Calculations of IC50 were determined using a 
four-parameter logistic sigmoidal fitting function 
within GraphPad Prism. Unless otherwise states, 
data is reported as mean ± standard deviation 
(SD). A significance level (P-value) of < 0.05 was 
considered as statistically significant. 
 
RESULTS  
 
Expression and localisation of BCRP in Z310 
cells 
The immortalised rat choroid plexus Z310 cell 
line has previously been used as an in vitro tool to 
study drug transport at BCFSB (37, 82). To date, 
only one study has confirmed the presence of 
BCRP in Z310 cells (37) and based upon this 
observation, we investigated the presence of 
BCRP in Z310 cells. Reverse–transcriptase PCR 
confirmed the presence of BCRP in Z310 cells 
with an expected product size of 146 base pairs 
alongside the presence of key choroid plexus 
phenotypic markers transthyretin (TTR) and β-
actin (BA) loading control (Figure 2A). 
Furthermore, Z310 were successful shown to be 
localised in Z310 cells when grown on cover slips 
and subjected to immunofluorescence staining 
(Figure 2B). 
 
Cytotoxicity studies 
A 24 hour MTT assay across a seven-fold log 
concentration range (0.001 µM-1000 µM) showed 
no significant cytotoxicity for the majority of the 
modulators studied up to 100 µM, with the lowest 
cellular viability IC50 attributed to α-
napthoflavone (IC50=1.4 µM) with all remaining 
modulators demonstrated an IC50 in excess of 148 
µM (Figure 3).  
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 Figure 2. (A) Amplicon products for TTR, loading control (BA) and BCRP; (B) Localisation of BCRP in Z310 cells. 
Cells were grown on the coverslips for 2-3 days. Z310 cells were fixed with 4% paraformaldehyde and stained for 
BCRP using the ABCG2-M70 primary antibody and goat anti-rabbit IgG-FITC secondary antibody (Green). Cell 
nuclei were visualized using DAPI (Blue).  Negative excludes ABCG2-M70 primary antibody but includes FITC 
secondary, whereas positive includes primary and secondary antibody incubation for BCRP detection. 
 
 
Hoechst 33342 intracellular accumulation 
assay  
The functional activity of BCRP was evaluated by 
measuring the accumulation of H33342, a 
fluorescent BCRP substrate, following incubation 
of H33342 in the presence of modulators and 
Ko143. Exposure of cells to the BCRP specific 
inhibitor Ko143, resulted in a significant increase 
(P < 0.001) in intracellular H33342 accumulation 
when compared to control (no inhibitor) and with 
all modulators demonstrating a highly significant 
increase (P<0.0001) in H33342 accumulation 
compared to control (Figure 4).  All modulators 
demonstrated background-equivalent fluorescence 
emission with no overlapping fluorescence with 
H33342 except for baicalin, fisetin and α-
napthoflavone. Furthermore biochanin-a, chrysin, 
quercetin, rutin and silymarin demonstrated 
significantly higher intracellular H33342 
accumulation when compared to Ko143 (Figure 
4).  
For the non-phytoestrogenic compounds 
(BAP, curcumin and 17-β-estradiol), significantly 
higher RFUs  compared to Ko143 were observed 
for 17-β-estradiol only (P<0.001), whilst BAP and 
curcumin demonstrated significantly higher RFU 
compared to control only (P<0.0001).
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 Figure 3. Cytotoxicity of modulators of BCRP on the Z310 cells line. Z310 cells were grown on a 96-well plate for 48 
hours and exposed to modulators over a concentration range of 0.001-1000 µM for 24 hours. Data for each modulator 
is reported as scatter points with up to 8 replications per compound in three independent experiments. ND: not 
determined. 
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. 
Figure 4. H33342 accumulation assay for BCRP function in Z310 cells. Cells were grown in a 96 well plate for 48 
hours and washed with warm HBSS supplemented and incubated for 24 hours with media containing, unless otherwise 
stated, 25µM of test compound. Subsequently cells were incubated with media containg H33342 for 1 hours and lysed. 
. Data is represented as mean ± SD of three independent experiments with n=6-8 wells for each modulator in each 
experiment. Significant differences between Ko143 and modulators are indicated above the appropriate error bars. * P 
≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤ 0.0001. 
 
 
Modulation of BCRP protein expression 
To investigate the effect of different modulators 
on BCRP protein expression, Z310 cells were 
incubated with modulators for 24 hours and 
western blotting employed to assess any change in 
BCRP protein expression. BCRP was successfully 
demonstrated to be expressed in Z310 cells with 
an expected size of 72 kDa (Figure 5A).  A 
significant increase in BCRP protein was 
observed for flavone (2.65 ± 0.12 fold), baicalin 
(2.42 ± 0.19 fold), hesperidin (2.43 ± 0.09 fold) 
and BAP (1.61 ± 0.17 fold) (Figure 5). 
Furthermore, a significant down-regulation in 
BCRP was observed for naringin (0.16 ± 0.07 
fold) and silymarin (0.22 ± 0.09 fold), quercetin 
(0.29 ± 0.08 fold) and 17-β estradiol (0.49 ± 0.11 
fold) (Figure 5A).  
 
In vitro BCSFB model: modulation of BCRP 
transport function 
In the presence of 1 µM of the BCRP specific 
inhibitor Ko143, a significant increase in the 
apical-to-basolateral transport of sulfasalazine 
was observed across all time points (P< 0.05) 
(Figure 6a).  Similarly modulators resulting in 
down-regulation of BCRP in western blots 
analysis (section 3.5), namely 17-β-estradiol 
(Figure 6c), naringin (Figure 6e) and silymarin 
(Figure 6f) also demonstrated a significant (P ≤ 
0.05) increase in sulfasalazine apical-to-
basolateral transport at the end of the study 
period. Baicalin (Figure 6b) and flavone (Figure 
6d) demonstrated an up-regulation of BCRP 
protein expression (Figure 5) but only baicalin 
demonstrated a significant decrease  (P ≤ 0.05) in 
the apical-to-basolateral transport of sulfasalazine 
at earlier time points (60 minutes to 150 minutes) 
when compared to control. 
The apparent permeability (Papp,AB) of 
sulfasalazine was found to be 1.32x10-6 ± 0.12 
x10-6 cm/s , and this was significantly increased to 
2.11 x10-6 ± 0.09 x10-6 cm/s when exposed to the 
specific BCRP inhibitor Ko143 (Table 3), 
demonstrating the functional activity of BCRP in 
Z310 cells.  Furthermore, naringin, silymarin and 
17-β-Estradiol also resulted in significant 
increases in sulfasalazine apical-to-basolateral 
permeability; 3.83x10-6 ± 0.34 x10-6 cm/s, 
3.33x10-6 ± 0.61 x10-6 cm/s and 2.01x10-6 ± 0.23 
x10-6 cm/s respectively (Table 3). 
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Figure 5. (A) Western blot results of modulator incubation with Z310 cells. Modulators were prepared in media to a 
final concentration of 25 µM (0.1 µM for α-napthoflavone) and incubated with cells for 24 hours followed by 
extraction of whole cell lysate and separation of protein on an 8% SDS-Polyacrylamide gel (75 µg/lane), incubated 
with antibodies and detection by ECL methods. (B) Fold-change in BCRP protein expression. Data is represented as 
mean ± SD of three independent experiments with statistically significant differences between control and modulator 
exposed conditions indicated as * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤ 0.0001. 
 
 
DISCUSSION 
 
The regulation of drug disposition into the brain 
and wider CNS is tightly governed by the 
impermeable nature of the BBB and BCSFB 
coupled with an increasingly important 
complement of drug transporter proteins which 
tightly regulate the brain and CNS 
microenvironment (2, 3, 7-12, 84).  The 
expression and impact of BCRP is now clearly 
recognised at the BBB and BCSFB (39, 40, 43-
45, 85-88).  Despite the existence of inhibitors of 
BCRP which have demonstrated an ability reverse 
the BCRP efflux phenotype in vitro and, to a 
limited extent in vivo (41, 42, 47-50), there yet 
remains a paucity in the identification of safe and 
effective modulators of BCRP function. 
A novel class of compounds that have gained 
interest as potential transporter modulation 
candidates are phytoestrogens, of which 
flavonoids are the most abundant class.  In this 
context, this study was designed to examine the 
impact of, primarily, flavonoid exposure on the 
expression and function of BCRP at the BCSFB 
using the rat choroid plexus Z310 cells lines 
which has previously been shown to express P-gp 
, MRP1 (80, 89) and BCRP (37).  
This present study has confirmed the 
expression of BCRP in Z310 cells using reverse-
transcriptase polymerase chain reaction, with an 
amplicon product of the expected size (146 base 
pairs), immunofluorescence confocal microscopy 
(Figure 2) and western blot analysis (Figure 5A) 
demonstrating the expression and localisation of 
BCRP in the rat choroid plexus, consistent with 
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Figure 6. Fraction of sulfasalazine transported across an in vitro BCSFB model in the absence and presence of BCRP 
modulators. Cells were grown on permeable insert and transport studies were performed on day 8 (TEER ≥ 60 Ω.cm2) 
using 25 µM of modulators. Data is represented as mean ± SD of three independent experiments and reported as the 
ratio of receiver concentration (CR) and initial donor concentration (CD). Statistically significant differences between 
control and modulator exposed conditions are indicated as * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001 and **** P ≤ 0.0001. 
 
 
reported expression and localisation studies in rats 
(90) (37) and (91).  Furthermore BCRP was 
demonstrated to be functionally active through 
both a fluorescent substrate (H33342) intracellular 
accumulation assay in the presence of the known 
specific BCRP inhibitor (Ko143) (Figure 4) and 
demonstrated a significantly increased H33342 (P 
< 0.001) intracellular accumulation (2.1 ±0.5 
fold).  Furthermore a monolayer-based permeable 
insert BCSFB model demonstrated an increased 
apical-to-basolateral transport of the BCRP 
substrate sulfasalazine in the presence Ko143 
(Figure 6a). 
We have, for the first time, demonstrated the 
cytotoxicity profile of a range of potential BCRP 
modulators at the BCSFB.  For all test compounds 
studied, the calculated cellular viability IC50 
values were in excess of 148 µM (Figure 3) and 
all possessed a dose-dependent cytotoxicity 
profile.  
Whilst there is limited data on the 
cytotoxicity of flavonoids and their derivatives on 
CNS-derived tissues, many of the flavonoids 
employed within this study have been utilised in a 
range of cell systems with reported cell viabilities 
and cytotoxicities which concur with our 
observations and thus may enable limited 
comparisons to be made for any potential 
cytotoxic effects (Table 4). 
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Table 3. Calculated apparent permeability (apical-to-basolateral) for sulfasalazine in the absence and presence of 
modulators of BCRP 
  
Apparent permeability 
Papp,AB (10-6 cm/s) SD (10-6 cm/s) 
Sulfasalazine 1.32 0.12 
+Ko143 2.11 ** 0.09 
+Flavone 1.24 0.19 
+Naringin 3.83 *** 0.34 
+Silymarin 3.33 *** 0.61 
+Baicalin 1.10 0.08 
+17-β-Estradiol 2.01 * 0.23 
Papp,AB was calculated for sulfasalzine alone, in the presence of Ko143 and following pre-incubation for 24 hours with 
modulators. Statistically significant differences between sulfasalazine alone and modulator exposed conditions are 
indicated as * P ≤ 0.05, ** P ≤ 0.01 and *** P ≤ 0.001. 
 
 
Despite paucity in flavonoid cytotoxicity data 
at the BCSFB and other neural tissues, our 
cellular viability IC50 values and cytotoxicity 
profiles reported are in agreement with reported 
observations in a wide range of in vitro cell 
systems and demonstrate both potentially limited 
toxicity at sub-100 µM exposure and, in principal, 
the ability for the flavonoids to penetrate into a 
range of different cell types. 
Interestingly α-napthoflavone demonstrates a 
low IC50 of 1.4 µM, which in contrast to other 
compounds used, was significantly lower.  Whilst 
there is a paucity of brain-derived cell viability 
IC50 values, α-napthoflavone is routinely used at 
sub-µM concentrations as a weak AhR agonist 
(0.01 µM-15 µM) (69, 101) and our reported 
cellular viability IC50 is within this range studied. 
The expected in vivo exposure is therefore an 
important element in attempting to discern any 
potential in vivo cytotoxicity.  In a microdialysis 
study brain concentrations of naringin were 
determined in rodents following a 100 mg/kg dose 
with a reported Cmax of 0.82 µg/mL (1.4 µM) 
(102). In a further study hesperetin was 
administrated as an IV bolus dose (50mg/kg) to 
rats and detected in the brain biophase with a Cmax 
of approximately 0.15 µg/mL (0.45 µM) (103). In 
relation to exposure of flavonoids in the CSF, data 
is limited but it has been suggested the 
concentrations are within the range of 1-5 µM 
(104). Despite this paucity, it is therefore apparent 
that the expected in vivo exposure would be 
within below the IC50 of many of the modulators 
studied.
 
 
Table 4. Reported cytotoxicity of flavonoids 
Flavonoid Extent of toxicity Cell Line 
Apigenin Limited cytotoxicity up to 100 μM HFIIE (92) 
Limited cytotoxicity up to 100 μM Rat C6 (92) 
Biochanin A No significant cytotoxicity between 2-100 μM during a 72-hour 
exposure MCF-10A and NIH-3T3 (93) 
Dose-dependent cytotoxicity SK-BR-3 (94)  
No toxicity up to 100 μM RAW264.7 (94) 
IC50=50 μM HT-9 (94) 
Fistein 27.6 % reduction in viability at 120 μM for 24 hours COLO205 (95) 
Hesperidin IC50=195 μM Caco-2 (96) 
IC50=230 μM CEM/ADR5000 (96) 
IC50=95 μM CCRF_CEM (96) 
Limited cytotoxicity at 100 μM with a viability of 53% SNU-668 (97) 
IC50=150 μM MSTO-211H (98) 
Quercetin No significant cytotoxicity between 20-80 μM RAW264.7 cells (99) 
Rutin Limited cytotoxicity up to 270 μM with a viability of 80% at 810 μM HTC (100) 
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BCRP has a highly diverse range of substrates 
and has been extensively reviewed elsewhere 
(105-107).  In this study we chose to utilise a 
commonly used probe substrate for BCRP, 
H33342 (108, 109), and take advantage of its 
fluorescent properties to assess the intracellular 
accumulation of H33342 (110) Using the known 
specific inhibitor for BCRP, Ko143 (43, 111), our 
accumulation results demonstrated a highly 
significant (P < 0.001) increase in the intracellular 
accumulation of H33342 (Figure 4), indicating the 
specific inhibition of BCRP-associated H33342 
efflux and concurring with other reports 
demonstrating the specific nature of BCRP 
inhibition when using Ko143 (43, 111). when 
compared to control cells, the exposure of 25 µM 
modulators to Z310 cells for 24 hours resulted in 
a statistically significant increase in H33342 
accumulation (P ≤ 0.0001) for all modulators 
studied.   Furthermore, when compared to Ko143 
a range of flavonoids demonstrated significantly 
increased intracellular accumulation of H33342 (P 
< 0.05: silymarin; P < 0.01: biochanin A, and 
quercetin; P < 0.001: chrysin and rutin). Although 
baicalin, fisetin and α-napthoflavone also 
demonstrated significantly increased intracellular 
accumulation of H33342, this should be viewed 
with caution when considering the inherent 
fluorescence emission observed overlapping with 
that of H33342. Furthermore 17-β-estradiol, a 
known potent BCRP downregulator (77), also 
demonstrated significantly increased intracellular 
accumulation of H33342 
As the mechanism of inhibition is not a direct 
competitive one, due to the pre-incubation period 
followed by a wash-out period in fresh incubation 
media, these effects suggest the modulators 
studied are able to impart an effect that is 
potentially unrelated to an effect on the substrate 
binding sites. To this end, we undertook a western 
blotting procedure to asses any discernible change 
in BCRP protein expression following similar 24 
hour incubation with modulators. 
Our results highlighted that out of the 18 
modulators studied, only 8 showed a statistically 
significant change in BCRP protein expression, 
with baicalin, hesperidin and flavone showing a 
BCRP up-regulation effect and naringin, 
quercetin and silymarin showing a down-
regulation effect (Figure 5). Of the non-
phytoestrogenic compounds the positive control 
used within this study (17-β-estradiol) 
demsontrated the expected trend of down-
regulation of BCRP.  This down regulation could 
be the result of interference with 17-β-estradiol 
signalling pathways by ERα and ERβ.  Imai et al 
(2005) (112)  demonstrated that 17-β-estradiol 
significantly reduced the expression of BCRP in 
MCF-7 cells at low nanomolar concentrations (3 
nmol/L) for 1,2 and 4 days (2-,5- and 10-fold 
down regulation respectively).  Furthermore, 
Hartz et al (2010) (77) found that the protein 
expression of BCRP was down regulated in the 
presence of 17-β-estradiol in rat brain capillaries. 
Of note is a 2.5-fold or greater change in 
BCRP expression when exposed to flavone, 
baicalin and hesperidin and a 0.16-0.49 fold 
decrease in BCRP expression when exposed to 
naringin, silymarin, quercetin and 17-β estradiol 
(Figure 5).  
In addressing the observed changes in BCRP 
expression, a study by Ebert et al (66) reported 
that 25 µM and 50 µM quercetin increased BCRP 
protein expression in human intestine carcinoma 
cells (Caco-2) by 2.6 and 5.3-fold following a 72-
hour incubation. On an mRNA level Ebert et al 
(66) also demonstrated a 19-37-fold increase in 
BCRP mRNA when exposed to 50 µM of chrysin, 
quercetin, resveratrol and flavone. 
Similarly, our studies demonstrated a 
significant down-regulation of BCRP expression 
with silymarin, but in Caco-2 cells Ebert et al (66) 
demonstrated increased expression.  Modulators, 
specifically flavonoids, have therefore been 
demonstrated to have the capacity to alter BCRP 
expression at the protein levels, although the 
differences in modulation between our study and 
those reported by Ebert et al (66) in Caco-2 cells 
may signify cell specificity in the change in 
protein expression and/or may suggest a time-
dependant effect. 
To be in a position to gauge the functional 
consequences of any change in BCRP expression 
we conducted a transport study using a permeable 
insert system.  The assay was developed by pre-
incubating cells, grown on a permeable insert 
system, for 24 hours with the modulator followed 
by a wash-out period and monitoring the transport 
of the BCRP substrate sulfasalazine (in the 
absence of any modulators) for the duration of the 
transport study.  We chose the BCRP specific 
inhibitor Ko143,  and the modulators baicalin, 17-
β- estradiol, flavone, naringin and silymarin to 
investigate and sulfasalazine as known BCRP 
substrate (114, 115).  Our initial studies were 
conducted with Ko143 and we observed a 
statistically significant increase in apical-to-
basolateral sulfasalazine flux across all time 
points when compared to control inserts (Figure 
6a) concurring with the presence of BCRP protein 
as indicated in the western blot analysis (Figure 
5a) and the functional direction of efflux transport 
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(basolateral-to-apical) and hence the inhibition of 
BCRP (increased apical-to-basolateral flux) at the 
BCSFB. 
Baicalin demonstrated a significant increase 
in protein expression (2.42 ± 0.19 fold) and was 
therefore chosen as a potential up-regulator of 
BCRP expression.  In the transport studies a 
significant decrease (P<0.05) in apical-to-
basolateral flux (approximately 10%) for a 
portion of the assay period (60-150 minutes) was 
observed, demonstrating the increasing 
basolateral-to-apical transport of sulfasalazine and 
hence diminishing the overall apical-to-
basolateral flux.  However, when examining the 
impact of flavone on BCRP, no significant 
differences were observed in apical-to-basolateral 
flux for the duration of the study. This was 
surprising as flavone demonstrated the greatest 
up-regulation of BCRP protein in western blots 
(Figure 5) and may indicate time-dependant 
protein decay following the up-regulation 
phenomena. 
When investigating the impact of the down-
regulators 17-β-estradiol, naringin and silymarin, 
we observed statistically significant differences 
across all time-points with a 8%, 40% and 26% 
increase in sulfasalazine transport, for 17-β-
estradiol (Figure 6c), naringin (Figure 6e) and 
silymarin (Figure 6f).  This was also translated 
into similar significant increases in the Papp,AB for 
these compounds (Table 3).  
Of interest is the translational effect of down-
regulation in BCRP protein when exposed to 
naringin and silymarin (0.16 ± 0.07 fold and 0.22 
± 0.09 fold change in protein expression, 
respectively, figure 5) and the resultant effect on 
‘CSF-to-blood’ sulfasalazine transport where 
Papp,AB for naringin and silymarin was increased 
by 2.9- and 2.5-fold, respectively. This effect 
clearly highlights the potential impact of 
prolonged exposure of flavonoids to BCRP may 
have on substrate transport and how this may 
influence the disposition of transporter substrate 
at the BCSFB and wider CNS. 
Given the paucity in reported data on the 
interaction of flavonoids of BCRP 
expression/function at the BCSFB, our western 
blot and functional transport studies concur with 
other similar results from Hartz et al (2010) (77) 
who demonstrated that 17-β-estradiol is able to 
down-regulate BCRP at the BBB. 
The question remains however, how effective 
will flavonoids be in vivo and will they reach 
sufficient levels to initiate such a response? The 
dietary intake of flavonoids provides the body 
with flavonoids which exist predominantly in 
planta as glycoside conjugates and which often 
possess limited absorption into the systemic 
circulation (116). Upon contact with lactase 
phloridzin hydrolase (LPH) at the brush border of 
the enterocyte, the aglycone is formed and is 
absorbed by passive diffusion (117). The final 
form found in the circulation is often the sulfate, 
glucuronide and/or methylated metabolites as a 
result of the action of sulfotransferases (SULT), 
uridine-5′-diphosphate glucuronosyltransferases 
(UGTs) and catechol-O-methyltransferases 
(COMT) (116). It is therefore unlikely that the 
conjugated form of the flavonoids would naturally 
be capable of crossing the BCSFB or BBB. 
Numerous studies have demonstrated that the 
aglycone is capable of transferring across the 
BBB. Naringenin and hesperetin (30 μM) have 
been demonstrated to be able to penetrate the 
BBB in two brain endothelial cell lines (mouse 
b.END5 and rat RBE4) and an in vitro model of 
the BBB (ECV304 cells co-cultured with C6 
glioma cells), with a significant level of uptake 
into b.END5 and RBE4 cells (hesperetin: 140 and 
146 ng/mg protein, respectively; naringenin:177 
and 127 ng/mg protein, respectively) (118), with 
the aglycone form of flavonoids demonstrating 
significantly greater penetration across the BBB 
compared to the conjugated form [aglycone: 
naringenin (Papp=350 nm/s) and hesperetin (Papp 
=290 nm/s); conjugated (Papp =113-182 nm/s)]. In 
a further study the aglycone form of [3H]-
naringenin was able to be detected in most brains 
regions using in situ perfusion studies in rats 
(119).  
Furthermore, in an in vivo study by Rangel-
Ordonez et al (2010) (120),  a standard extract of 
Ginkgo biloba (extract EGb761) was given to rats 
at a single dose of 600 mg/kg. Following this 
dose, only kaempferol and isorhamnetin were 
detected in brain tissues (293 ng/g brain). 
Furthermore, high concentrations of quercetin 
were detected in the hippocampus, stratum and 
cerebellum, with levels exceed 1000 ng/g brain 
protein. Peng et al., (1998) (121) demonstrated 
that the aglycone form of naringenin was detected 
in the cerebral cortex of rats following an IV 
bolus dose.  
It is clear that the aglycone form is capable of 
penetrating the BBB and therefore the delivery of 
such aglycone (and unconjugated) flavonoids are 
important. This has been demonstrated through 
approaches involved nanoparticulate delivery 
systems encapsulating often poorly soluble 
aglycone forms of flavonoids (Table 5). 
It is therefore envisaged that, at the BCSFB, 
the aglycone form of flavonoids would be able to 
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gain access to the chorodial epithelial cells to 
elicit a modulator effect on BCRP expression, 
with the potential benefit of a nanoparticulate 
carrier system enhancing the retention of the 
aglycone form within the circulation. 
Our studies have demonstrated that 
flavonoids can be utilised as potential modulators 
of BCRP function at the BCSFB, but the 
mechanism of the observed changes are important 
in the understanding of how flavonoids can be 
adapted to be useful.  BCRP has been reported to 
be modulated by a number of nuclear receptors 
including peroxisome proliferator-activated 
receptor α (PPARα) in human immortalised 
hCMEC/D3 cells (132, 133), nuclear factor kB 
(NF-kB) in primary (134) and immortalised 
(hCMEC/D3) (135) brain endothelial cells, 
pregnane X receptor (PXR) and constitutive 
androstane receptor (CAR) (136, 137), esteogen 
receptors in rodent brain capillaries (77) (138) and 
recently the aryl hydrocarbon receptor (AhR) (66, 
139-142).   
The regulation of BCRP has clearly been 
demonstrated in a range of tissues but a complete 
understanding of its role at neural tissues is still 
lacking. The exact mechanism by which BCRP 
regulation is precisely controlled therefore 
warrants further study, particularly considering 
there is evidence to suggest that flavonoids are 
capable of permeating the BBB and/or the 
BCSFB, for example quercetin (119, 143); 
catechin and epicatechin (144); hesperetin, 
naringenin, epicatechin and their glucuronides 
(118) and kaempferol and isorhamnetin (120) are 
capable of permeating the BBB and/or the 
BCSFB and therefore have the potential to 
interact with any of these regulatory elements. 
A potentially novel application of the 
modulation of the regulatory control of drug 
transporter proteins was recently reported by 
Hartz et al (2010) (145) using an Alzheimer's 
disease rodent model.  Using this model the 
expression of P-glycoprotein at the BBB was 
found to be reduced, leading to the accumulation 
of the neurotoxic peptide β-amyloid in neural 
tissues. Hartz et al (2010) (145) was able to 
demonstrate that the restoration of P-glycoprotein 
expression through, PXR activation, resulted in 
the reduction of brain levels of β-amyloid.  Thus, 
further work is required to ascertain the exact 
mechanism of regulatory control of BCRP during 
prolonged exposure to flavonoid and how this 
could be adapted to enhance the distribution of 
therapeutic agents into the brain and wider CNS. 
 
CONCLUSION 
 
We have, for the first time, successfully 
demonstrated the ability of flavonoids to 
modulate the protein expression of BCRP at the 
BCSFB.  Furthermore, our studies have 
demonstrated that flavonoids are generally 
expected to show limited cytotoxicity at the 
BCSFB with naringin and silymarin possessing 
the characteristics of potent down-regulators of 
BCRP protein at the BCSFB which translated into 
a significant increase in CSF-to-blood passage of 
drug, potentially providing an opportunity to alter 
the CNS disposition patterns of drugs.  It is 
important to further elucidate the mechanism of 
such regulatory changes, whether genomic via 
nuclear receptors or non-genomic in nature, and 
furthermore the in vivo impact on BCRP substrate 
transports the BCSFB. 
 
 
Table 5. Encapsualtion and targeting of phytoestrogens to the CNS 
Phytoesteogen nanoparticles Payload Species 
PLGA Quercetin and catechin (122) In vitro 
Quercetin and etoposide (123) Rats 
Nanographene oxide Quercetin (124) In vitro 
Non-phytoestrogen nanoparticles 
PLA (125) Rats 
Chitosan (126) Rats 
Albumin nanoparticles (127) Mice 
Functionalised nanoparticles 
Gelatin-soloxane TAT-peptide (128, 129) Mice 
Ritonavir loaded TAT-conjugated PLA nanoparticles (130) Mice 
Transferrin anchored pegylated albumin nanoparticles (131) Rats 
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